
Patient-Reported Outcome Consortium
The Patient-Reported Outcome Consortium supports patient-focused drug development by obtaining qualification of clinical outcome assessment tools that measure how patients feel and function in their everyday lives as a result of treatment.
News
-
Aug 5, 2022 PRO Consortium Announces Publication of Open Access Article
-
Jul 25, 2022 Diary for Irritable Bowel Syndrome Symptoms-Constipation Now Available for Licensing
-
Jun 8, 2022 PRO Consortium Announces Publication of Open Access Article
-
May 20, 2022 eCOA Consortium and PRO Consortium Announce Publication of Open Access Article
Past Events
More Events >>Publications
-
Jul 19, 2022 Comparing patient global impression of severity and patient global impression of change to evaluate test–retest reliability of depression, non-small cell lung cancer, and asthma measures
-
Jun 8, 2022 Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ): measurement properties and estimated clinically meaningful thresholds from a phase 3 study
-
May 16, 2022 Recommendations for the Electronic Migration and Implementation of Clinician-Reported Outcome Assessments in Clinical Trials
-
Sep 13, 2019 Symptoms of Major Depressive Disorder Scale: Performance of a Novel Patient-Reported Symptom Measure
-
Sep 6, 2018 Response scale selection in adult pain measures: results from a literature review
Relevant Links
PRO Consortium Measures and Licensing Information
BEST (Biomarkers, EndpointS, and other Tools) Resource
Division of Clinical Outcome Assessment (DCOA)
COA Qualification Program Website
Drug Development Tool (DDT) Qualification Website – FDA
Guidance for Industry: Multiple Endpoints in Clinical Trials (Draft)
Guidance for Industry: Qualification Process for Drug Development Tools
Guidance: Search all FDA official guidance documents and other regulatory guidance